NYSE: PFEPfizer

    Pfizer Q3 2026 Results: Net Income $3.24 Billion on Revenue of $16.58 Billion

    • US stocks
    • Earnings
    • Health Care
    Two clear glass laboratory tubes lying on a pale surface, one with a few dark specks inside
    B.Lachner, via Wikimedia Commons (CC0). Illustrative image.

    Pfizer (NYSE: PFE) reported GAAP revenue of $16.6 billion and GAAP net income of $3.24 billion for the third quarter of 2026, and it said on 3 Nov 2026. GAAP diluted EPS was $0.56, and adjusted diluted EPS, a company-defined measure, was $0.87.

    Key highlights

    • Revenue (GAAP): $16.6 billion, down 0.4% YoY and up 10.3% QoQ
    • Net income (GAAP): $3.24 billion, down 8.4% YoY
    • Diluted EPS (GAAP): $0.56, down 9.7% YoY
    • Adjusted diluted EPS (company-defined): $0.87, the same as a year earlier
    • Full-year 2026 adjusted diluted EPS guidance (company-defined): $2.95 to $3.05, previously $2.80 to $3.00

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoYQ2 2026QoQ
    Revenue16,583.016,654.0-0.4%15,034.0+10.3%
    3,242.03,541.0-8.4%-248.0n/a
    Diluted EPS ($)0.560.62-9.7%-0.04n/a

    Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 27 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    Against the third quarter of 2025, GAAP revenue fell 0.4%, GAAP net income fell 8.4% and GAAP diluted EPS fell 9.7%. GAAP net income was 19.6% of revenue, against 21.3% a year earlier, 1.7 percentage points lower.

    Against the previous quarter, GAAP revenue rose 10.3%, to $16.6 billion from $15.0 billion. GAAP net income was $3.24 billion, against a net loss of $248.0 million in the previous quarter.

    Adjusted figures exclude amortization and certain significant items

    The company's adjusted income, a measure it builds by leaving out amortization of intangibles, certain acquisition-related items and certain significant items, was $4,985 million, against $4,949 million a year earlier. Adjusted diluted EPS was $0.87 in both periods.

    Eliquis and Padcev led the operational gains

    Eliquis revenue was $2.52 billion, up 25% on an operational basis. The company said this came mainly from higher U.S. net price and higher demand globally, partly offset by generic entry and price erosion in some international markets.

    Padcev revenue was $720 million, up 55% operationally. The company cited higher market share in first-line urothelial cancer and launch uptake in cisplatin-ineligible muscle-invasive bladder cancer. Paxlovid fell 63% to $449 million, and the company attributed that decline to lower COVID-19 infections, partly offset by timing of government purchases in certain emerging markets. Comirnaty fell 30% to $808 million.

    Excluding Comirnaty and Paxlovid, revenue grew 7% operationally. R&D expenses were $3.02 billion, up 18% operationally, and the company said it anticipates a net increase in spending on certain oncology and obesity candidates.

    Outlook raised for 2026

    The company now expects 2026 revenue of $62.0 billion to $64.0 billion, up from $60.5 billion to $62.5 billion, and adjusted diluted EPS of $2.95 to $3.05, narrowed from $2.80 to $3.00.

    The adjusted EPS outlook includes a one-time $650 million acquired IPR&D charge for the Innovent Biologics, Inc. agreement, which the company said has an unfavorable impact of about $0.10 per share. The company also expects about $1.1 billion of unfavorable revenue impact from generic and biosimilar competition. Its guidance assumes no share repurchases in 2026 and no business development deals not completed by 3 Nov 2026.

    Adjusted SI&A expense is guided to $12.5 billion to $13.5 billion, and adjusted R&D expense to $10.8 billion to $11.8 billion, up from $10.5 billion to $11.5 billion. The adjusted tax rate is about 15.0%.

    Inference

    The quarter used 5,751 million diluted weighted-average shares, against 5,714 million a year earlier. For the first nine months of 2026, cash dividends totaled $7.3 billion, or $1.29 per share. No share repurchases had been completed in 2026 as of 3 Nov 2026, and $3.3 billion remained under the authorization.

    The release does not give a quarterly dividend per share, free cash flow or a third-quarter operating income figure.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Related posts

    All Pfizer articles